Cadazolid: A new hope in the treatment of Clostridium difficile infection.

Abstract

Clostridium difficile infection (CDI) is a potential life-threatening consequence of antibiotic therapy. Although the risk increases with duration of treatment, it can also occur after a short treatment course. In addition to broad-spectrum antibiotics, anti-neoplastic agents, proton pump inhibitors, H(2) blockers, and several other drugs have been reported to induce intestinal dysbiosis, which is central to the pathogenesis of CDI. There is an increase in incidence and mortality attributed to CDI globally. Moreover, the epidemiology of C. difficile-associated diseases has changed significantly with an increasing occurrence of community-acquired CDI. Metronidazole and oral vancomycin are the first-line antibiotics used to treat CDI. However, metronidazole has limited effectiveness in severe cases and vancomycin use is associated with increasing risk of vancomycin resistance among Enterococcus spp. Cadazolid, a novel oxazolidinone antibiotic, has recently shown potent antimicrobial activity against C. difficile and has a lower propensity to induce resistance. The implications of its use in treating CDI have been reviewed based on current evidence.

• Authors: Arunava Kali, Marie Victor Pravin Charles, Srirangaraj Srirangaraj
• Journal: The Australasian medical journal (Australas Med J) Vol. 8 Issue 8 Pg. 253-62 ( 2015) ISSN: 1836-1935 [Print] Canada
• PMID: 26392822 (Publication Type: Journal Article, Review)